Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women (Q36366167)

13 August 2017

1 reference

title

Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women (English)

1 reference

13 August 2017

0 references

1 reference

1 reference

1 reference

Lourdes Ibáñez

1

1 reference

13 August 2017

Francis de Zegher

series ordinal

2

1 reference

13 August 2017

publication date

11 January 2006

1 reference

Human Reproduction Update

13 August 2017

published in

1 reference

13 August 2017

volume

12

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

243-252

1 reference

Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Fulminant liver failure associated with flutamide therapy for hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

The prevalence and features of the polycystic ovary syndrome in an unselected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Androgen excess in women: experience with over 1000 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Current concepts in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Metformin treatment of PCOS during adolescence and the reproductive period

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Androgen receptor antagonists (antiandrogens): structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Endothelial inflammation in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Thiazolidinediones for treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Hepatotoxicity Induced by Antiandrogens: A Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Combined oral contraceptives in the treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

21 January 2018

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1093%2FHUMUPD%2FDMI054

21 January 2018

Identifiers

DOI

10.1093/HUMUPD/DMI054

1 reference

13 August 2017

1 reference